18.09.2013 12:10:00
|
Daiichi Sankyo Company, Limited -- Moody's: US FDA's Import Alert on Ranbaxy Is a Credit Negative for Daiichi Sankyo
Tokyo, September 18, 2013 -- The US Food and Drug Administration's (FDA) import alert on Ranbaxy (not rated) is a credit negative because it highlights continued challenges faced by Daiichi Sankyo's (A1, stable) ability to execute its hybrid business strategy.